Shionogi

Shionogi says the Artificial Intelligence Statistical Programming System, released in September 2023, enables AI to automatically generate the SAS statistical analysis programs required for clinical trials and achieved a 30% reduction in standard work hours.

Shionogi says the Generative AI Group, established in October 2024, is advancing the development, implementation and internal deployment of operational support systems that use generative AI. The same page says the company aims to use generative AI large language models for efficiency and quality in medical writing, including protocols and clinical study reports.

Shionogi said a generative-AI solution for drafting regulatory documents in drug development was built by combining its medical writers' knowledge and its data scientists' AI design work with Hitachi's generative-AI know-how. A proof of concept at the company confirmed about a 50% reduction in clinical study report preparation time and about a 20% reduction in protocol preparation time. The same release says Shionogi licensed the solution to Hitachi, which began offering it to pharmaceutical and healthcare companies in Japan in February 2026.

Partners: Hitachi

On its risk-management page, Shionogi lists business-model and operations reform through practicing AI drug discovery among the responses to its digital-transformation risk.

The same risk-management list includes market inventory prediction using AI as part of Shionogi's business-model and operations reform.

FRONTEO and Shionogi announced a strategic business partnership for dementia-related and depression-related AI programs. Through the partnership they will use FRONTEO's natural-language-processing AI technology to develop diagnostic-support AI models and related medical and non-medical devices.

Partners: FRONTEO

Shionogi and NEC announced a strategic research collaboration for a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary the release describes as specializing in artificial-intelligence-driven biotechnology, is also participating. The release says the companies will accelerate progress toward the vaccine by combining Shionogi's infectious-disease discovery capability with NEC's expertise in artificial intelligence.

Partners: NEC, NEC OncoImmunity

Shionogi said it had concluded a research collaboration with InveniAI on AI-powered multi-target drug discovery in psycho-neurological disease using AlphaMeld. The release describes AlphaMeld as an AI drug-discovery platform that identifies multiple targets related to a specific disease and the mechanisms for treating those diseases.

Partners: InveniAI

Shionogi announced the Innovation Centre in Digital Molecular Technologies, an open consortium with the University of Cambridge and AstraZeneca for automated and digitalized chemical synthesis of molecules such as drugs. The release says the consortium aims to innovate chemistry practice by integrating high-throughput synthesis, analytics, chemical informatics, machine learning, robotics and reaction engineering.

Partners: University of Cambridge, AstraZeneca